A28. From Review to Reality: How Feedback is Shaping the Medicines Australia Code 19 Review
Tracks
Medical Operations
| Wednesday, June 12, 2024 |
| 4:30 PM - 5:30 PM |
| Parkside 2 |
Chair & Speakers
Samar Alrawi
Regional Medical Specialist - Asia Pacific
(MSD) Merck Sharp & Dohme (Australia) Pty Limited
Chair: From Review to Reality: How Feedback is Shaping the Medicines Australia Code 19 Review
Biography
Samar Alrawi is a multifaceted professional with a distinguished career in the pharmaceutical industry. She has held various roles across different companies and therapeutic areas, demonstrating her leadership prowess by spearheading Medical Information and Pharmacovigilance, including serving as the Australian QPPV, at both the country and regional levels. Currently positioned at Merck Sharp & Dohme (MSD) as a Regional Medical Specialist across the Asia-Pacific markets, she commands the oncology and infectious disease therapy areas and is currently transitioning to assume Global responsibilities. With a background in law and biological science, majoring in molecular biology, supplemented by a graduate certificate in Pharmaceutical Medicine and Drug Development, she leverages her industry expertise to drive impactful outcomes.
Sophie Seck
Senior Manager, Ethics and Compliance @ Medicines Australia
Medicines Australia
From Review to Reality: How Feedback is Shaping the Medicines Australia Code 19 Review
Abstract
In this session, we consider the current review of Medicines Australia’s Code of Conduct Edition 19 and tease out your perspectives as we strive to ensure the Code is representative of real-world experiences.
Pharmaceutical companies operating in Australia and other key stakeholders were invited to provide input during the consultation window of April and May. The co-presenters will talk through some of the priority areas identified in the Consultation Paper and what we are hearing in response to those areas.
The session explores these questions and invites your contribution and discussion on:
• To what extent does Code Edition 19 accommodate new and emerging technologies used for communication with healthcare professionals? How can it be improved to recognize new technologies?
• Does Code Edition 19 provide sufficient guidance to companies as to how they can provide educational information about medical conditions and treatments? And in what ways could the Code be clearer in relation to these materials?
• Is the concept of "scientific exchange” sufficiently clear? Is there a better way of describing the types of roles with the appropriate knowledge and experience that could engage in non-promotional scientific exchange which reflects different models of working within companies?
Reflections from the session will be provided back to the Code Review process, which wraps up in October 2024.
Pharmaceutical companies operating in Australia and other key stakeholders were invited to provide input during the consultation window of April and May. The co-presenters will talk through some of the priority areas identified in the Consultation Paper and what we are hearing in response to those areas.
The session explores these questions and invites your contribution and discussion on:
• To what extent does Code Edition 19 accommodate new and emerging technologies used for communication with healthcare professionals? How can it be improved to recognize new technologies?
• Does Code Edition 19 provide sufficient guidance to companies as to how they can provide educational information about medical conditions and treatments? And in what ways could the Code be clearer in relation to these materials?
• Is the concept of "scientific exchange” sufficiently clear? Is there a better way of describing the types of roles with the appropriate knowledge and experience that could engage in non-promotional scientific exchange which reflects different models of working within companies?
Reflections from the session will be provided back to the Code Review process, which wraps up in October 2024.
Biography
Sophie is an experienced Manager with a demonstrated history of working in the non-profit organisation management sector. She has worked across multiple sectors, managing industry Codes of Conduct that set down and agreed way of practice; and her roles have been to manage and administer those Codes through promotion, education, assessment and managing a rigorous complaints mechanism. Key to her experience has been membership engagement, stakeholder management, continuing education, and communications & governance.
Deborah Monk
Medicines Australia (consultant)
From Review to Reality: How Feedback is Shaping the Medicines Australia Code 19 Review
Abstract
In this session, we consider the current review of Medicines Australia’s Code of Conduct Edition 19 and tease out your perspectives as we strive to ensure the Code is representative of real-world experiences.
Pharmaceutical companies operating in Australia and other key stakeholders were invited to provide input during the consultation window of April and May. The co-presenters will talk through some of the priority areas identified in the Consultation Paper and what we are hearing in response to those areas.
The session explores these questions and invites your contribution and discussion on:
• To what extent does Code Edition 19 accommodate new and emerging technologies used for communication with healthcare professionals? How can it be improved to recognize new technologies?
• Does Code Edition 19 provide sufficient guidance to companies as to how they can provide educational information about medical conditions and treatments? And in what ways could the Code be clearer in relation to these materials?
• Is the concept of "scientific exchange” sufficiently clear? Is there a better way of describing the types of roles with the appropriate knowledge and experience that could engage in non-promotional scientific exchange which reflects different models of working within companies?
Reflections from the session will be provided back to the Code Review process, which wraps up in October 2024.
Pharmaceutical companies operating in Australia and other key stakeholders were invited to provide input during the consultation window of April and May. The co-presenters will talk through some of the priority areas identified in the Consultation Paper and what we are hearing in response to those areas.
The session explores these questions and invites your contribution and discussion on:
• To what extent does Code Edition 19 accommodate new and emerging technologies used for communication with healthcare professionals? How can it be improved to recognize new technologies?
• Does Code Edition 19 provide sufficient guidance to companies as to how they can provide educational information about medical conditions and treatments? And in what ways could the Code be clearer in relation to these materials?
• Is the concept of "scientific exchange” sufficiently clear? Is there a better way of describing the types of roles with the appropriate knowledge and experience that could engage in non-promotional scientific exchange which reflects different models of working within companies?
Reflections from the session will be provided back to the Code Review process, which wraps up in October 2024.
Biography
Ms Deborah Monk
Deborah holds a Bachelor of Pharmacy from the University of Sydney and a Diploma in Hospital Pharmacy. She also holds a Bachelor of Arts from Macquarie University and a Masters in Public Policy from the University of Sydney
Deborah started her working life as a clinical pharmacist in the Pharmacy Department at a major teaching hospital in Sydney. She joined the Australian Pharmaceutical Manufacturers Association (APMA), as Medicines Australia was formerly known, in mid-1989 as a Projects Officer in Scientific and Technical Affairs.
Before retiring in December 2019, Deborah had worked for Medicines Australia for more than 30 years. Her final role was Director of Ethics and Compliance and Corporate Services and Secretary to the Medicines Australia Board.
Recognising her experience in leading multiple reviews and updates to the Medicines Australia Code of Conduct, including Code Edition 19, Deborah has been invited to assist Medicines Australia with the 2024 review of the Code.
